Matrixyl
A collagen fragment attached to a fatty acid so it can cross the skin barrier. One of the few cosmetic peptides with a published double-blind trial showing wrinkle improvement.
Skin & Cosmetic
Matrixyl 3000
A two-peptide successor to Matrixyl, pairing a collagen signal with an anti-inflammatory fragment. Evidence is largely supplier-generated.
Overview
Matrixyl 3000 combines two palmitoylated peptides rather than one. The first is a GHK fragment that signals for collagen and matrix production. The second is intended to reduce the low-grade inflammation that drives matrix breakdown, on the reasoning that building more collagen matters less if you are not also slowing its destruction. Independent published trials are thin — most of what exists comes from the ingredient supplier.
A combination of palmitoyl tripeptide-1 (pal-GHK) and palmitoyl tetrapeptide-7 (pal-GQPR). Pal-GHK acts as a matrikine promoting collagen I, III and fibronectin synthesis; pal-GQPR is derived from an immunoglobulin sequence and is proposed to reduce interleukin-6 production, limiting inflammation-driven matrix metalloproteinase activity. Palmitoylation provides stratum corneum permeation for both. The published efficacy data is predominantly supplier-generated with instrumental endpoints; independent randomised trials with blinded clinical assessment are scarce.
Research areas
PhotoageingCollagen synthesisMatrix inflammation
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Topical application at supplier-recommended concentration twice daily over 8–12 weeks | Ingredient supplier technical documentation |
Trial status
Supplier-generated studies with instrumental endpoints. Limited independent replication.
Reported safety signals
- Well tolerated topically.
- Efficacy evidence is weaker and less independent than for the original Matrixyl.
- Injection has no published basis or safety data.
Common questions
Is Matrixyl 3000 an upgrade on Matrixyl?
It is a different formulation, not a demonstrated improvement. The original pal-KTTKS has a published independent vehicle-controlled trial behind it; Matrixyl 3000's evidence is largely from the company that sells the ingredient. Newer is not automatically better-evidenced.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →